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A unique subset of y6 T cells, termed dendritic epidermal T 
cells (DETC) , resides in symbiosis with keratinocytes in 
mouse epidermis. W e have shown previously that interleu-
kin 7 (IL-7) which is produced by keratinocytes, promotes 
groW"th and prevents ~poptosis in I?ETC. To exten~ th!s 
observation, we examll1ed 12 cytokll1es, each of which IS 
expressed by eJ:>i.dermal cells at mRNA and/or protein levels, 
for their capaCities to modulate the growth ofDETC. Cyto-
kines examined included IL-1a, IL-2, IL-3 , IL-4, IL-6, IL-7, 
IL-8, IL-10, tumor necrosis factor-a (TNFa), interferon-y 
(IFNy), granulocyte/macrophage-colony stimulating fac-
tor (GM-CSF), and macrophage inflammatory protein-1a 
(MIP-la) . When tested individually, IL-2 and IL-7 pro-
moted maximal growth of the long-term cultured DETC 
line 7-17. When tested in combinations, synergistic growth-
promoting effects were seen with IL-2 and IL-4 or IL~7 , and 
w ith IL-7 and IL-4 or TNFa. Dose-response expenments 
T he concept of immune regulation by cytokines pro-duced in the epidermis can be dated to the discovery that keratinocytes elaborate interleukin-1 (IL-1) [1- 3]. Keratinocytes, which possess overwhelming numerical superiority in mammalian skin, are now 
known to produce a spectrum of cytokines, including IL-1a, IL-l{J, 
IL-3 , IL-6, IL-8, granulocyte/macrophage colony-stimulating fa~­
tor (GM-CSF) , and tumor necrosis factor a (TNFa) (reViewed 111 
[4 - 6]). Recently, IL-7 and IL-I0 ~ave b~en added t.o this list [7,8]. 
In mice, keratlnocytes live 111 symbIOSIS With two reSident leukocyte 
populations: Langerhans cell s and dendritic epidermaJ T cells 
(DETCs). W e and others have shown that Lan?erhans cell.s, whi~h 
are antigen-presentmg cells of dendritiC cell llI1eage (reViewed 111 
[9]), are capable of expressing mRNA for and/or secreting at least 
three cytokines, IL-1{J, IL-6, and macrophage 1I1fIammatory pro-
tein-lll'(MIP-1a) [10-12] . DETCs, which are CD3+, CD4-, 
CD8-, yt5 T-cell receptor (Tc ny, arc one member of a family of ~6 
T cells that reside preferentially in epithelial tissues (reViewed 111 
[13, 14]). DETCs, also a source of cytokines, arc known to secrete 
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demonstrated that TNFa, which is produced by keratino-
cytes, enhances IL-7 - induced DETC proliferation, but in-
hibits IL-2 - induced proliferation. The mouse keratinocyte-
derived cell line Pam 212 was used to test these cytokines for 
their capacities to regulate keratinocyte growth. Only yIFN , 
which is produced by DETC, inhibited proliferation in a 
dose-dependent fashion. These results illustrate three recip-
rocal pathways by which epidermal cytokines regulate the 
growth of epidermal cells: 1) a paracrine mechanism by 
which keratinocyte-derived cytokines (e.g., IL-7 and TNFa) 
promote the growth of DETC, 2) an autocrine mechanism 
by which DETC-derived cytokines (e.g ., IL-2 and IL-4) sup-
port their own growth, and 3) a reciprocal pathway in which 
a cytokine produced by resident epidermal leukocytes (e. g., 
yIFN) modulates the growth of keratinocytes. Key words: 
epidermal y6 T cell/keratinocyte/ growth/ cytokine. ] Invest 
Dermatoll 01 :543 -548, 1993 
IL-2, IL-3 , IL-4, and interferon-Y(IFNY) [15 -17], and recently we 
have observed that they also express mRNA for IL-la, IL-6, IL-7, 
TNFa, TNF{J, GM-CSF, and MIP-la. * 
An important issue, then, is the role these cytokines play in regu-
lating their own epidermal microenvironment. In fact, several ke-
ratinocyte-derived cytokines, i. e., IL-la, GM-CSF, and TNFa, 
have been shown to promote the growth and/or the maturation of 
Langerhans cells [18 - 21] . Likewise, we have shown that keratino-
cyte-derived IL-7 serves as a growth factor for DETCs. t Moreover, 
IL-7 prevents apoptotic cell death that would ordinarily be induced 
in DETCs when exposed to exogenous corticosteroids.:j: Thus, ke-
ratinocytes support the growth and survival of these two resident 
epidermal leukocytes through the elaboration of relevant cytokines 
and growth factors. In the present study, this line of investigation 
was extended by examining 12 cytok ines, all of which are likely to 
be present under normal or pathologic circumstances in mouse epi-
. • Matsue H, Cruz PD Jr, Bergstresser PR, Takashima A: Profiles of cyto-
kllle mRNA expressed by dendritic epidermal T cells in mice.) !rlllesl Derma-
to/1 01 :537 -542, 1993 (Ihis issue) . 
t Matsue H, Bergstresser PR, Takashima A: Keratinocyte-derived IL-7 
serves as a growth factor fo r dendritic epidermal T cells (manuscript submit-
ted). 
t Matsue H, McDowall A, Bergstresser PR, Takashima A: Keratinocyte-
derived IL-7 rescues dendritic epidermal T cells from apoptosis (manuscript 
submitted). 
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Table I. Cytokine mRNA Expression by Mouse Epidermal 
Cell Subpopulations 
Cytok ine BC' KC Line' Thy-l +EC' DETC LineJ 
IL-l a + + + 
IL- IP + 
IL-2 + 
IL-3 + + 
IL-4 ±f 
IL-5 + + 
IL-6 + + 
IL-7 + + 
TNFa + + 
TNFP + + 
IFNy ± + 
GM-CSF + + 
MIP-la + 
IL-8 [53] 
IL-I0[8] 
• Epidermal sheet preparation or epidermal cell suspension. 
, Pam 212 keratinocyte line. 
' FACS-purificd Thy- 1+ epidermal cells (DETe). 
J Short or long-term DETC lines. 
, PACS-purificd la+ epidermal cells (Langerhans cells). 
f Faint signal. 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
dermis, for their potential to modul ate the growth of both DETCs 
and keratinocytes. 
MATERIALS AND METHODS 
Cells The long-term cultured DETC line 7-17 was used for these experi-
ments. :rhis line was first established from AKR mice by culturing fluores-
cence-activated ce ll sorter (FACS) - purified DETCs with 2Jig/ml Con A 
and 5 U/ml lL-2 [22]. 7-17 DETCs have been maintained by repeated 
restimu lation with 1 Jig/ml Con A (every 1- 3 weeks) and by feeding with 
human r1L-2 (R&D Systems, Minneapolis, MN). The culture medium has 
been RPMI 1640, supplemented with 10% fetal bovine serum (FBS) , 
10 mM HEPES, 1 % nonessential amino acids , 10 jiM sodium pyruvate, 
20 jiM L-glutamine, 1% penicillin/streptomycin, and 50 jiM 2-mercap-
toethanol (complete RPMI) [1 5,23]. At the time of use, cells were harvested 
by a 3-min incubation with 1 mM ethylenediaminetetraacctic acid (EDTA), 
10 mM HEPES in Hanks' balanced salt solution. 7-17 DETCs have retained 
the phenotype of DETCs ill sitll. They are Thy-l +, CD3+, ap TCR- , yo 
T CR+, and V y3/Vol +, as judged by FACS analyses using the following 
monoclonal antibodies (MoAb): anti-Thy-1.1 (Becton Dickinson, Moun-
tainview, CAl, anti-CD3e (kindly provided by Dr. J. Allison, University of 
Cali fornia, Berkeley, CAl, anti-ap T CR (Pharmingen, San Diego, CAl, 
anti-yoTCR (Pharmingen), anti-Vy3 (Pharmin gen) , and 17Dl, a.n antibody 
that recognizes the V y3/Vol TCR (kindly provided by Dr. R. E. Tigelaar, 
Highest dose Day 2 
None 
IL-la (Jng/ml) 
Figure 1. Promotion of DETC prolif- IL-2 (10ng/ ml) 
eration by epidermal cytokines. 7-17 IL-3 (100ng/ml 
DETCs were stimulated with Con A IL- + (12.5ng/ml) 
and tes ted 2 d later for proliferative re-
sponsiveness to selected cytokines, at IL-6 (25ng/ml) 
three different concentrations: high IL-7 (25ng/ml) 
(shown in parfllthcses), med ium (five IL-8 (25ng/ml) 
times di lution) , and low (25 times dilu- IL- l 0 (5ng/ ml) 
tion). Data shown are the means ± 
SEM (n = 3) for 3 H-thymidine incor- TN Fa (25ng/ ml) 
poration harvested on day 2 (lift) or day GJ.4 -CSF (50ng/ ml) 
5 (right). J.4IP- la (25ng/ml) 
-yIFN (5OOng/ml) 
50 
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Yale University). 7-17 DETCs have been used extensively by several inves-
tiga tors, and their other characteristics are described elsewhere [1 6,24,25]. 
BALB/c mouse keratinocyte-derived Pam 212 cells [26] were maintained 
as described previously [27]. Briefly , ce lls were cultured in Dulbecco's mini-
mum essential medium (DMEM) supplemented with the same additives 
used to supplement RPMI1 640 (complete DMEM). 
Cytokines Mouse r1L-1 a, r1L-3, rIL-4, rIL-8, rTNFa, rGM-CSF, and 
rINFy, and human rIL-8 were purchased from Genzyme (Cambridge, MA); 
mouse rIL-6, rlL-7, and rMIP-1 a, and human rIL-2 were from R&D Sys-
tcms; and mouse rIL-l 0 were from Bachem Bioscience, (Philadelphia, PAl. 
Proliferation Assays Cell proliferation was determined as described pre-
viously [15,23,27]. Briefly, 7-17 DETCs were pre-acti vated with Con A 
(1 Jig/ml) for 18 h, washed extensively, and then cultured for 1-3 d in the 
absence of added IL-2. These cells were then harvested with EDTA, plated 
(3 X 104 cells/well) in 96 round-bottom well -plates (Corning, Corning, 
NY), and cultured for up to 5 d in the presence of each cytokine or cytokine 
combination. Cells were pulsed with 1 JiCi/well of 3H-thymidine (New 
England Nuclear, Boston, MA) during the last 16 h, and harvested using an 
automated cell harvester (PHD, Cambridge, MA). Pam 212 keratinocytes 
isolated from semi-confluent culturcs were plated in 96 fl at-bottom well-
plates, cultured, and pulsed as above. T hese adherent ce lls required a brief 
treatment with trypsin prior to harvesting, as described previously [27]. All 
the data were analyzed for statistical significance by t test for independent 
samples using Kwikstat 3.3 (TexaSoft). 
Dexamethasone Treatment ofDETCs DETC apoptosis was induced 
with dexamethasone (DEX) as described previously.:!: Briefly, 7-17 DETCs 
(1 X 105 cells/well) in a resting state (activated with Con A 9-14 d previ-
ously) were cultured in complete RPM! in 24-well plates, in the presence or 
absence of DE X (1 X 10- 7 M) . After 20 h, ce lls were harvested with EDTA, 
and cell viability was assessed by trypan blue exclusion; at least 400 cells were 
counted per sample. 
RESULTS 
IL-2 and IL-7 are Major Growth Factors for DETCs As de-
scribed in the Irltroduction, eac h of th e epidermal cell subpopulations 
(i. e., keratinocytes, Lan gerhans cells, and DETCs) elaborates a dis-
tinct profil e o f cytokines. Results from o ur reverse-transcription-
polymerase chain reactio n analyses are summarized in Table I, 
which lists cytokine mRNAs expressed by fres hl y isolated epider-
mal cells, Pam 212 keratinocytes, FAC S-purified DETCs, short-
and lon g-term DETC lines, and FACS-purified Langerhans cells. 
The term "epidermal cytokines" will be used to identify all of these 
cytokines as a group (IL-la, IL-1/J, IL-2, IL-3 , IL-4, IL-6, IL-7 , 
IL-8, IL-I0, IFNy, TN Fa, G M -CSF, ;Uld MIP-la) . 
In the first set of experime nts, each epiderm al cytokine was tested 
individually for its capacity to m odulate DETC proliferation . Rep-
resentative results from three independent experime nts are shown 
100 
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Figure 2. Synergistic effects of epider-
mal cytokines on DETC prolIferatIOn. 
7-17 DETCs stimulated with Con A 
2 d previously were cultured in the 
resence of rIL-2 (2 ng/m l) (A) or rIL-~ (5 ng/ml) (B). Other cytokines were 
also added at three different concentra-
tions (see Fig 1) to these cultures. Data 
shown are the means ± SEM (n = 3) 
fo r 3H-thymidine incorporation har-
vested on day 2 (left) or day 5 (right). B 
None 
IL-la 
IL- 2 
IL-J 
IL-4 
IL-6 
IL-8 
IL- l 0 
TNFa 
GM-CSf 
MIP-la 
rlfN 
Day 2 
50 100 
in Fig 1. To begin, 7-17 DETCs showed minimal 3H-thymidine 
incorporation on days 2 and 5, in the absence of added growth 
factors (Fig 1). This baseline proliferation was clearly upregulated 
by added IL-2, with significant activiry detected even at t!le lowest 
concentration (0.4 ng/ml) and l!1creasll1g progressively, l!1 a dose-
dependent fashion. IL-7 (1-25 ng/ml) also exhibited marked 
growth-promoting activiry. Importantly, IL-2 and IL-7 promoted 
DETC growth with different kinetics. IL-2 - induced proliferation 
occurred rapidly, with substantial 3H-thymidine incorporation on 
day 2 and less by day 5. By contrast, IL-7 responses were modest on 
day 2 but remained at that level even on day 5 (Fig 1) . Both IL-4 and 
TNFa showed modest, but statistically significant (p < 0.01), ac-
tivities on day 2: 900 ± 50 cpm (baseline), 2400 ± 200 cpm (12.5 
ng/m1 IL-4~, and 2800 ± 40 cpm ~2~ ng/ml TN~a) . All other 
cytokines failed to promote or to l!11ublt DETC proliferatIOn under 
the conditions employed for these experiments. 
3 H_ Thymidine incorporation (cpm xl 0-3) 
CJLow 
rlDAMedium 
_High 
150 200 
N.D. 
N.D. 
N.D. 
N.D. 
N.D. 
N.D. 
Day 5 
20 40 
3 H_ Thymidine incorporation (cpm x l 0 - 3 ) 
60 
TNFa Augments IL-7 -Induced DETC Proliferation In the 
next set of experiments, epidermal cytokines were tested in several 
combinations. In two independent experiments, both IL-4 and IL-7 
consistently augmented IL-2 - induced proliferation of DETCs on 
day 5 (Fig 2A). These effects were synergistic ratber than additive 
(p < 0.05); the magnitudes of proliferation were 510 ± 130 cpm 
(IL-2), 370 ± 60 cpm (IL-4), 21,000 ± 500 cpm (IL-7) for individ-
ual cytokines, and 5,900 ± 1,400 cpm (IL-2 plus IL-4), and 
35,000 ± 1,300 cpm (IL-2 plus IL-7) in combinations. 
When tested in combination with IL-7 , three cytokines (IL-2, 
IL-4, and TNFa) also showed a synergistic augmentation (p < 
0.01) of proliferative responses on both day 2 and day 5 (Fig 2B). For 
example, the magnitudes of proliferation on day 5 were 20,000 ± 
1,600 cpm (IL-7) , 460 ± 50 cpm (IL-2), 370 ± 60 cpm (IL-4), 
240 ± 40 cpm (TN Fa) for the individual cytokines, and 32,000 ± 
2,000 cpm (IL-7 plus IL-2) , 39,000 ± 120 cpm (IL-7 plus IL-4), and 
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Figure 3. TNFO' amplifies IL-7-induced DETC proliferation. 7-17 
DETCs stimulated with Con A 3 d previously were cultured in the presence 
of rIL-2 (2 ng/ml) (A) or rIL-7 (5 ng/ml) (B). rTNFO' was also added to 
these cultures at the indicated concentrations. Data shown are tbe means ± 
SEM (n = 3) for the percent of control (in the absence ofTNFO') on day 2 
(lift) or day 5 (right). 
58,000 ± 2,000 (IL-7 plus TNFa) in combinations. These resu lts 
illustrate both autocrine and paracrine mechanisms by which 
DETC proliferation is promoted by DETC-derived cytokines (IL-2 
and IL-4) and by keratinocyte-derived cytokines (IL-7 and TNFa), 
respectively. 
To study the regulatory effect of TNFa more closely, its dose 
response was examined in combination with IL-2 or IL-7. Surpris-
ingly, TNFa was found to inhibit IL-2-induced DETC prolifera-
tion (Fig 3A). The IL-2-induced response on day 5 (8,400 ± 1,200 
cpm) was inhibited 60% with TNFa, with the effective TNFa 
concentration in the range between 1.6 and 8 ng/ml. By marked 
contrast, TNFa augmented IL-7 - induced DETC proliferation 
(Fig 3B), an effect that was most prominent on day 2. The IL-7 
response (6,600 ± 1,200 cpm) was amplified up to threefold by 
added TNFa, with this activity occurring at concentrations be-
tween 8 and 200 ng/ml. Importantly, proliferative responses to 
TNFa alone were negligible « 1 000 cpm at each data point). Thus, 
we conclude that TNFO' augments IL-7 - induced DETC prolifera-
tion but inhibits IL-2-induced proliferation. 
IL-2, IL-4, and IL-7 Prevent Dexamethasone-Induced DETC 
Death W e have observed previously that 7-17 DETCs undergo 
apoptosis in response to ill lIitro treatment with DEX.:j: Cellular 
changes have included 1) reduced cell viability (trypan blue exclu-
sion),2) DNA fragmentation (DNA laddering ill electrophoresis), 
3) a requirement for macromolecule biosynthesis (inhibition by 
cycloheximide or actinomycin D), and 4) chromatin condensation 
and loss of microvilli (electron microscopy), all of which typify cells 
that are undergoing apoptosis (reviewed in [28]). When IL-7 was 
added simultaneously with the DEX, apoptosis did not occur.:j: It 
was, therefore, of particular interest to determine whether DETC 
apoptosis can be induced or prevented by other epidermal cytokines . 
First, none of the cytokines induced significant cell death in 7-17 
DETCs in the absence of DEX in any of the three independent 
experiments (Fig 4, left). When the same cytokines were tested for 
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Figure 4. Effects of epidermal cytokines on DETC survival. 7-17 DETCs 
stimulated with Con A 10 d previously were cultured for 20 h in 96-well 
plates (1 X 105 cells/wel l) in the presence (right) or absence (left) of DEX 
(1 X 10- 7 M). Cytokines were tested at the "medium" concentrations listed 
in Fig 1. Data shown are the means ± SEM (n = 2) of cell viabilities as 
determined by trypan blue exclusion. 
their ability to prevent DEX-induced cell death, three cytokines, 
IL-2, IL-4, and IL-7, consistently showed significant activities (p < 
0.05); cell viabilities were 98% (no DEX), 47% (DEX alone), 98% 
(DEX plus IL-2), 91 % (DEX plus IL-4) , and 98% (DEX plus IL-7) 
(Fig 4, right panel). Relatively modest effects were also observed, but 
only occasionally, with several other cytokines (i.e., IL-10, TNFa, 
GM-CSF, and MIP-1a). 
yIFN Inhibits the Growth of Pam 212 Keratinocytes Having 
confirmed the biologic activities of epidermal cytokines on DETC 
proliferation and apoptosis, additional experiments were conducted 
to determine whether these same cytokines would modulate the 
function of other epidermal cells. In the absence of stable lines of 
Langerhans cells, and recognizing the comprehensive studies of 
Steinman and his colleagues [19- 21,29], we chose to limit this 
examination to the effects of these epidermal cytokines on keratino-
cyte growth . Pam 212 keratinocytes were tested for their prolifera-
tive responses to added cytokines with two protocols : 1) relatively 
large numbers of cells, with harvesting on day 2 (Fig SA), and 2) 
fewer cells, with harvesting on day 5 (Fig 5B). In both protocols, 
3H-thymidine incorporation was measured with cells in the expo-
nential growth phase, as indicated with arrows in the left panel of 
Fig 5. Pam 212 cell growth was clearly inhibited by added IFNI', 
under both protocols (p < 0.05 at 20 ng/ml, and p < 0.01 at 100 
ng/ml IFNy). Maximal activity (40- 60% inhibition) was achieved 
at a IFNI' concentration of 1 00 ng/ml. All other cytokines failed to 
promote or to inhibit the growth of this keratinocyte line in two 
independent experiments. 
DISCUSSION 
The reported experiments tested 12 different epidermal cytokine 
for their potential to modulate the growth ofDETCs and keratino-
cytes. The most striking observations were that IL-7 and TNFa, 
both of which are produced by keratinocytes [7,30], promote the 
growth of DETCs, in a synergistic fashion . IL-7, which was first I 
characterized as a bone marrow stroma cell-derived pro- and pre -
B-cell growth factor [31,32]' has also been demonstrated to serve as 1 
a growth factor for early lymphoid cells of both B- and T-cell 
lineages (reviewed in [33]). In addition to mature T cells, IL-7 also 
promotes the proliferation of thymocytes [34 - 36] and in our earlier 
report, we observed that IL-7 also promotes the growth ofDETC. t 
Recently, it has become evident that TNFa has the capacity to 
promote the growth of early thymocytes, especially when com-
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Figure 5. Effects of epidermal cytokines on 
PaIn 212 keratinocyte proliferation. Pam 212 
keratinocytes were plated in 96 flat-bottom-
well plates at 5 X 103 cells/well (A) or 1 X 103 
cells/well (B). Cytokines were tested at "me-
dium" concentrations listed in Fig 1, except 
that IFNI' was added at three different concen-
rrations: 500 ng/ml (H), 100 ng/ml (M), and 
20 ng/ml (L). Data shown are the kinetics of 
proliferation (mean ± SEM, n = 3) in the ab-
sence of cytokines (left) and the 3H-thymidine 
incorporation (mean ± SEM, n = 3) in the 
presence of cytokines on day 2 (A) or day 5 (B) . 
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bined with other cytokines (e.g. , IL-2 and IL-7) [37 -39). Thus, our 
results suggest that DETCs, which are also derived from thymic 
~ precursors and express the identical TCR (i.e., Vy3/VJ1) to that 
found on day 16 thymocytes [40,41], resemble early thymo~ytes .in 
their g rowth-factor requirements as well. Thus, these findmgs il-
lustrate paracrine mechanisms by which cytokines (e.g., IL-7 and 
TNFa) produced by neighboring keratinocytes promote the 
growth of epidermal resident yo T cells. 
IL-2 also induced marked proliferation of 7-17 DETCs, corro-
borating our previous observations with DETCs freshly procured 
from skin (23) . On the other hand, IL-4 synerglzed With IL-2 or 
IL-7 to enhance DETC proliferation substantially. We and others 
have shown that DETCs are capable of producing these two cyto-
h nes [15,17] , and our recent reverse transcription - polymerase 
chain reaction analyses demonstrated that mRNA for IL-2 and IL-4 
are expressed exclusively by DETCs among the epidermal cell sub-
populations. * Thus, these pathways through IL-2 and IL-4 most 
likely represent relevant autocrine mechanisms. 
Our observation that IL-la and IL- IO failed to modulate DETC 
growth was unexpected, because these two cytokines have also. been 
considered to regulate T -cell growth m other systems. IL-l prmlar-
ily serves as a co-stimulatory factor in T-cell activation processes, by 
upregulating mitogen/antigen-induced IL-2 production and IL-2 
receptor expression [42,43]. Therefore, our assays, in which prolif-
erative responses of pre-activated DETCs were measured, may not 
be ideal to detect possible effects ofIL-i. IL-I0, which is also pro-
duced by keratinocytes (8) , has been shown to modulate thymo-
cyte/m ature T -cell proliferation (reviewed in [44]). Again, our 
assays may not be suitable for detecting IL-lO effects, because this 
cytokine appears to act primarily on antigen-presenting cells by 
downregul ating their function to activate T cells [45] or to affect 
cytokine production by a particular T-cell subset [46). Because 
DE~C proliferation in these assays is independent of antigen-pre-
sentl11g cells, It will be necessary to examine the possible roles 
played by IL-1 and IL-10 in assay systems in which DETC growth 
may rely on antigen-presenting cells. 
We also sought to determine proliferative respouses of keratino-
cytes to epidermal cytokines. Among the cytokines tested, IL-1, 
IL-6, and TNFa have been reported to upregulate keratinocyte 
growth: 1) IL-l !l a~ been implicated as being responsible for epider-
mal hyperplas ia mmflammatory skl11 disorders [47]; 2) IL-6, which 
also promotes the growth of human keratinocytes, is overexpressed 
m psonatlc skm, agall1 suggestmg its role in epidermal hyperplasia 
[48]; and 3) TNFa promotes the growth of human papillomavirus-
mfected keratll10cytes m an autocrine mechanism [49]. In other 
systems, however, the growth of human keratinocytes was not af-
fected by added IL~ 1 or IL-6 [50) . Our inabili ty to detect a growth-
promoting potential for these three cytokines most likely reflects 
the fact that each of these factors is produced endogenously (at least 
at mRNA levels) by the Pam 212 keratinocytes used in our study, 
leadll1g to the pOSSibility that their effects were already operative 
(Table I) [1,2]. TI1lS assumption is supported by the unambiguous 
effect of IF N y, which is produced by DETCs but not by Pam 212 
cells [1 6]. * In fact, this pronounced inhibition of cell growth, attrib-
utable to IFN~, has been observed in other systems [51,52). T hus, 
these observations Illustrate at least one pathway by which cyto-
kmes produced by a resident epidermal leukocyte regulate the 
growth of keratinocytes . 
In summary, we have demonstrated that epidermal cell subpopu-
lations in mouse skin may affect each other through the elaboration 
of relevant cytokines. Three distinct mechanisms were illustrated: 
1) a paracrine mechanism in which keratinocyte-derived cytokines 
(e.g., IL-7 and TNFa ) promoted the growth of DETCs; 2) an 
autocrine mechanism in which DETC-derived cytokines (e.g. , IL-2 
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and IL-4) supported their own growth; and 3) a reciprocal paracrine 
mechanism in which a cytokine produced by a resident leukocyte 
modulated the growth of keratinocytes. 
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